XLV is a breakout after an extended period of under performance. Biotech, one of our bellwethers for XLV, has improved. IYW has had strong selling since the last Sector Review, and this sector has been extended for some time. The risk is that the “Fang Stocks” are moving from strong to weak hands and could do badly for a while.
Sorry this page is available to subscribers only. If you're not a subscriber why not join today?